Infantile Neuroaxonal Dystrophy (Inad) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Infantile neuroaxonal dystrophy (INAD), also known as [PLA2G6-associated neurodegeneration (PLAN)[/diseases/[pla2g6-associated-neurodegeneration[/diseases/[pla2g6-associated-neurodegeneration[/diseases/[pla2g6-associated-neurodegeneration--TEMP--/diseases)--FIX-- or Seitelberger disease, is a rare autosomal recessive neurodegenerative disorder belonging to the group of [neurodegeneration with brain iron accumulation (NBIA)[/diseases/[neurodegeneration-brain-iron-accumulation[/diseases/[neurodegeneration-brain-iron-accumulation[/diseases/[neurodegeneration-brain-iron-accumulation--TEMP--/diseases)--FIX-- disorders 1(https://www.ncbi.nlm.nih.gov/books/NBK1675/). The disease is caused by biallelic mutations in the PLA2G6 gene, which encodes the calcium-independent phospholipase A2 group VI enzyme (iPLA2-VIA), and is characterized pathologically by widespread neuroaxonal spheroids — swollen, degenerating axon terminals found throughout the central and peripheral nervous system 2(https://pmc.ncbi.nlm.nih.gov/articles/PMC12287646/).
INAD is the most severe form within the PLA2G6-associated neurodegeneration (PLAN) spectrum, which encompasses three overlapping phenotypes based on age of onset: infantile neuroaxonal dystrophy (INAD, onset 6 months to 3 years), atypical neuroaxonal dystrophy (aNAD, onset 4 years to young adult), and PLA2G6-related dystonia-parkinsonism (adult onset) 1(https://www.ncbi.nlm.nih.gov/books/NBK1675/). The estimated incidence of INAD is approximately 1 in 100,000 to 200,000 live births, though the true prevalence may be higher due to underdiagnosis 3(https://rarediseases.org/rare-diseases/infantile-neuroaxonal-dystrophy/).
The disease was first described by Seitelberger in 1952, who reported the distinctive neuropathological hallmark of axonal spheroids composed of accumulations of tubulovesicular structures and mitochondria within dilated axon terminals 2(https://pmc.ncbi.nlm.nih.gov/articles/PMC12287646/). The genetic basis was identified in 2006 when mutations in PLA2G6 were found to be causative.
¶ Genetics and Molecular Biology
The PLA2G6 gene is located on chromosome 22q13.1 and encodes the group VIA calcium-independent phospholipase A2 (iPLA2-VIA or iPLA2β), a 85-kDa enzyme that hydrolyzes the sn-2 acyl bond of glycerophospholipids to release free fatty acids, including arachidonic acid 1(https://www.ncbi.nlm.nih.gov/books/NBK1675/). Over 200 pathogenic variants have been identified, including missense, nonsense, frameshift, and splice-site mutations 4(https://pubmed.ncbi.nlm.nih.gov/24745848/).
The iPLA2-VIA enzyme plays critical roles in multiple cellular processes 2(https://pmc.ncbi.nlm.nih.gov/articles/PMC12287646/):
- Membrane phospholipid remodeling: Maintains membrane integrity and fluidity by regulating fatty acid composition of phospholipids
- Mitochondrial membrane homeostasis: Essential for maintaining cardiolipin composition and [mitochondrial dynamics[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics--TEMP--/entities)--FIX--
- Calcium signaling: Modulates store-operated calcium entry and intracellular calcium homeostasis
- Inflammation regulation: Generates lipid mediators involved in inflammatory and anti-inflammatory pathways
- [autophagy[/entities/[autophagy[/entities/[autophagy[/entities/[autophagy--TEMP--/entities)--FIX--: Regulates autophagosome-lysosome fusion and autophagic flux
Loss of iPLA2-VIA function triggers multiple downstream pathological cascades 2(https://pmc.ncbi.nlm.nih.gov/articles/PMC12287646/):
- Mitochondrial dysfunction: Impaired mitochondrial membrane composition leads to defective electron transport chain function, reduced ATP production, and increased generation of [reactive oxygen species[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX--
- Lipid peroxidation and [ferroptosis[/mechanisms/[ferroptosis[/mechanisms/[ferroptosis[/mechanisms/[ferroptosis--TEMP--/mechanisms)--FIX--: Accumulation of oxidized phospholipids, particularly phosphatidylethanolamine, triggers iron-dependent lipid peroxidation
- Iron accumulation: Dysregulated lipid metabolism promotes brain iron deposition, linking INAD to the broader [NBIA[/diseases/[nbia[/diseases/[nbia[/diseases/[nbia--TEMP--/diseases)--FIX-- disease spectrum and [ferroptosis[/mechanisms/[ferroptosis[/mechanisms/[ferroptosis[/mechanisms/[ferroptosis--TEMP--/mechanisms)--FIX-- mechanisms
- Impaired [autophagy[/entities/[autophagy[/entities/[autophagy[/entities/[autophagy--TEMP--/entities)--FIX--: Defective autophagic clearance leads to accumulation of damaged organelles and protein aggregates
- Ceramide accumulation: Altered [sphingolipid metabolism[/mechanisms/[sphingolipid-metabolism[/mechanisms/[sphingolipid-metabolism[/mechanisms/[sphingolipid-metabolism--TEMP--/mechanisms)--FIX-- contributes to neuronal apoptosis
- Axonal degeneration: Combined metabolic stress leads to formation of neuroaxonal spheroids — the pathological hallmark of the disease
INAD typically presents between 6 months and 3 years of age with a characteristic clinical progression 1(https://www.ncbi.nlm.nih.gov/books/NBK1675/) 3(https://rarediseases.org/rare-diseases/infantile-neuroaxonal-dystrophy/):
Stage 1 — Early symptoms (6 months to 2 years):
- Progressive psychomotor regression with loss of previously acquired milestones
- Truncal hypotonia (floppy baby) — compare with [hypotonia[/conditions/[hypotonia[/conditions/[hypotonia[/conditions/[hypotonia--TEMP--/conditions)--FIX-- in metabolic disorders
- Strabismus and nystagmus
- Diminished social interaction and reduced responsiveness
Stage 2 — Progressive deterioration (2–4 years):
- Spastic tetraparesis (limb [spasticity[/diseases/[hereditary-spastic-paraplegia[/diseases/[hereditary-spastic-paraplegia[/diseases/[hereditary-spastic-paraplegia--TEMP--/diseases)--FIX-- replacing initial hypotonia)
- [Optic atrophy[/conditions/[optic-atrophy[/conditions/[optic-atrophy[/conditions/[optic-atrophy--TEMP--/conditions)--FIX-- with progressive visual loss
- Marked cognitive decline and loss of speech
- Bulbar dysfunction (swallowing difficulties)
- Fast rhythmic movements of the hands or feet (characteristic rapid nystagmus-like limb movements)
Stage 3 — Advanced disease (4+ years):
- Complete loss of voluntary movement
- Profound intellectual disability
- Blindness
- Frequent [seizures[/diseases/[epilepsy[/diseases/[epilepsy[/diseases/[epilepsy--TEMP--/diseases)--FIX--
- Progressive dysphagia requiring gastrostomy
- Respiratory complications
Death typically occurs between ages 5 and 10 years, though some patients survive into their second decade with supportive care 1(https://www.ncbi.nlm.nih.gov/books/NBK1675/).
The later-onset variant presents in childhood through young adulthood with 4(https://pubmed.ncbi.nlm.nih.gov/24745848/):
- Gait instability and cerebellar [ataxia[/diseases/[spinocerebellar-ataxia[/diseases/[spinocerebellar-ataxia[/diseases/[spinocerebellar-ataxia--TEMP--/diseases)--FIX--
- [Dystonia[/diseases/[dystonia[/diseases/[dystonia[/diseases/[dystonia--TEMP--/diseases)--FIX-- and spasticity
- Speech deterioration
- Neuropsychiatric features (behavioral changes, emotional lability)
- Slower progression than classic INAD
Adult-onset PLAN mimics early-onset [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX-- with 1(https://www.ncbi.nlm.nih.gov/books/NBK1675/):
- Levodopa-responsive parkinsonism with early dyskinesias
- Dystonia (often prominent)
- Cognitive and psychiatric features
- Pyramidal signs
Brain MRI reveals characteristic findings that aid diagnosis 5(https://www.neurology.org/doi/10.1212/01.wnl.0000310986.48286.8e) 4(https://pubmed.ncbi.nlm.nih.gov/24745848/):
- Cerebellar atrophy: Progressive cortical cerebellar atrophy is the most consistent finding, present in virtually all INAD patients
- Iron accumulation: T2-weighted hypointensity in the [globus pallidus[/brain-regions/[globus-pallidus[/brain-regions/[globus-pallidus[/brain-regions/[globus-pallidus--TEMP--/brain-regions)--FIX-- (present in approximately 40–50% of INAD patients, more common in later disease stages)
- Cerebellar gliosis: T2 hyperintensity in the cerebellar [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--
- White matter abnormalities: Periventricular white matter signal changes
- Corpus callosum thinning: Vertically oriented, thin corpus callosum
- Clava hypertrophy: Enlargement of the gracile tubercle in the medulla, a relatively specific finding
- Electromyography (EMG): Denervation pattern consistent with motor neuron or axonal neuropathy
- Nerve conduction studies: Reduced motor and sensory nerve conduction velocities
- Electroencephalography (EEG): High-voltage fast rhythms, a relatively distinctive feature of INAD
Tissue biopsy (skin, conjunctiva, peripheral nerve, or rectal mucosa) may demonstrate the characteristic neuroaxonal spheroids — swollen, dilated axons containing accumulations of tubulovesicular structures, membranous profiles, and mitochondria 6(https://pmc.ncbi.nlm.nih.gov/articles/PMC11356075/). However, biopsy has been largely supplanted by genetic testing.
Identification of biallelic pathogenic variants in PLA2G6 on molecular genetic testing confirms the diagnosis 1(https://www.ncbi.nlm.nih.gov/books/NBK1675/). This is now the gold standard for diagnosis.
The brain shows 2(https://pmc.ncbi.nlm.nih.gov/articles/PMC12287646/):
- Severe [cerebellar] cortical atrophy
- Variable cerebral atrophy
- Pallor of the globus pallidus (iron deposition in some cases)
The hallmark is the presence of axonal spheroids (neuroaxonal dystrophy) 6(https://pmc.ncbi.nlm.nih.gov/articles/PMC11356075/):
- Distribution: Widespread throughout the gray matter of the central nervous system, particularly in the [basal ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia--TEMP--/brain-regions)--FIX--, [thalamus[/brain-regions/[thalamus[/brain-regions/[thalamus[/brain-regions/[thalamus--TEMP--/brain-regions)--FIX--, [cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum--TEMP--/brain-regions)--FIX--, [brainstem[/brain-regions/[brainstem[/brain-regions/[brainstem[/brain-regions/[brainstem--TEMP--/brain-regions)--FIX--, and spinal cord
- Composition: Dilated axon terminals filled with tubulovesicular structures, mitochondria, neurofilaments, and membranous profiles
- Cerebellar pathology: Severe [Purkinje cell[/cell-types/[purkinje-cells[/cell-types/[purkinje-cells[/cell-types/[purkinje-cells--TEMP--/cell-types)--FIX-- loss with torpedo-shaped axonal swellings, Bergmann gliosis
- Iron deposition: Prussian blue-positive iron deposits in the globus pallidus in a subset of cases
¶ Treatment and Management
¶ Current Standard of Care
There is currently no curative treatment for INAD. Management is focused on multidisciplinary supportive and palliative care 3(https://rarediseases.org/rare-diseases/infantile-neuroaxonal-dystrophy/) 7(https://pmc.ncbi.nlm.nih.gov/articles/PMC12084665/):
- Physical therapy: Maintain range of motion, prevent contractures
- Occupational therapy: Adaptive equipment and positioning
- Speech-language therapy: Swallowing assessment and communication strategies
- Nutritional support: Gastrostomy tube placement for dysphagia
- Seizure management: Antiepileptic [medications[/treatments/[anti-epileptic-drugs[/treatments/[anti-epileptic-drugs[/treatments/[anti-epileptic-drugs--TEMP--/treatments)--FIX--
- Respiratory care: Secretion management, respiratory support as needed
- Pain management: Assessment and treatment of discomfort
BGT-INAD (Bloomsbury Genetic Therapies) is the most advanced gene therapy candidate for INAD 8(https://bloomsburygtx.com/pipeline/bgt-inad/):
- AAV-based gene therapy delivering functional PLA2G6 via intracerebroventricular (ICV) administration
- Preclinical studies in neonatal and juvenile PLA2G6-INAD mice showed significantly extended survival, improved motor functions, and ameliorated neurodegeneration in multiple brain regions
- Received Orphan Drug Designation from both the European Commission and FDA
- Received Rare Pediatric Disease Designation from the FDA
Several small-molecule therapies have shown promise in preclinical models 9(https://elifesciences.org/articles/82555):
- Ambroxol: Lysosomal function enhancer
- Desipramine: Acid sphingomyelinase inhibitor
- Azoramide: Endoplasmic reticulum stress modulator
- Genistein: [autophagy[/entities/[autophagy[/entities/[autophagy[/entities/[autophagy--TEMP--/entities)--FIX-- inducer
These compounds were identified through screening of 20 drugs targeting relevant pathways and demonstrated efficacy in both INAD fly models and patient-derived neural progenitor cells 9(https://elifesciences.org/articles/82555).
INAD shares pathogenic mechanisms with several other neurodegenerative conditions:
- [NBIA[/diseases/[nbia[/diseases/[nbia[/diseases/[nbia--TEMP--/diseases)--FIX--: INAD/PLAN is classified as NBIA type 2 (NBIA2), sharing iron accumulation pathology with [PKAN[/diseases/[pkan[/diseases/[pkan[/diseases/[pkan--TEMP--/diseases)--FIX-- (NBIA1) and other NBIA subtypes
- [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--: Adult-onset PLA2G6 mutations cause [dystonia[/diseases/[dystonia[/diseases/[dystonia[/diseases/[dystonia--TEMP--/diseases)--FIX---parkinsonism (PARK14), linking PLAN to [Lewy body[/diseases/[dementia-lewy-bodies[/diseases/[dementia-lewy-bodies[/diseases/[dementia-lewy-bodies--TEMP--/diseases)--FIX-- pathology
- [Pantothenate Kinase-Associated Neurodegeneration (PKAN)[/diseases/[pantothenate-kinase-associated-neurodegeneration-pkan[/diseases/[pantothenate-kinase-associated-neurodegeneration-pkan[/diseases/[pantothenate-kinase-associated-neurodegeneration-pkan--TEMP--/diseases)--FIX--: Most common NBIA subtype; both feature [basal ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia--TEMP--/brain-regions)--FIX-- iron accumulation
- [Leigh Syndrome[/diseases/[leigh-syndrome[/diseases/[leigh-syndrome[/diseases/[leigh-syndrome--TEMP--/diseases)--FIX--: Shared features of mitochondrial dysfunction and progressive neurodegeneration in infancy
- [Lysosomal Dysfunction[/mechanisms/[lysosomal-dysfunction[/mechanisms/[lysosomal-dysfunction[/mechanisms/[lysosomal-dysfunction--TEMP--/mechanisms)--FIX--: Impaired autophagic-lysosomal pathways contribute to both PLAN and many other neurodegenerative diseases
- [ferroptosis[/mechanisms/[ferroptosis[/mechanisms/[ferroptosis[/mechanisms/[ferroptosis--TEMP--/mechanisms)--FIX--: Iron-dependent lipid peroxidation is emerging as a key pathogenic mechanism
- [Gene Therapy for Neurodegenerative Diseases[/treatments/[gene-therapy[/treatments/[gene-therapy[/treatments/[gene-therapy--TEMP--/treatments)--FIX--
The study of Infantile Neuroaxonal Dystrophy (Inad) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Link)
- [Infantile neuroaxonal dystrophy: Molecular mechanisms and pathogenesis of PLA2G6-associated neurodegeneration. AIMS Neuroscience. 2025;12(2]:178-207. Link)
- [PLA2G6-Associated Neurodegeneration. National Organization for Rare Disorders (NORD]. Link)
- [PLA2G6-associated neurodegeneration (PLAN]: further expansion of the clinical, radiological and mutation spectrum. Brain. 2014;137(Pt 7):1995-2013. Link)
- [Phenotypic spectrum of neurodegeneration associated with mutations in the PLA2G6 gene (PLAN]. Neurology. 2008;70(18):1623-1629. Link)
- [Infantile Neuroaxonal Dystrophy: Case Report and Review of Literature. Cureus. 2024;16(8]:e66652. Link)
- [Consensus Clinical Management Guideline for PLA2G6-Associated Neurodegeneration (PLAN]. PMC. 2025. Link)
- [BGT-INAD. Bloomsbury Genetic Therapies. Link)
- [Exploring therapeutic strategies for infantile neuronal axonal dystrophy (INAD/PARK14]. eLife. 2023;12:e82555. Link)
- [Neurodegeneration with Brain Iron Accumulation: Diagnosis and Management. Current Neurology and Neuroscience Reports. 2015;15(3]:18. Link)
- Link)